IRVINE, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Praxsyn Corporation (OTCQB:PXYN), the parent company of Mesa Pharmacy, today announced that it has begun to process PPO prescriptions. Mesa Pharmacy is dedicated to providing medical practitioners with medications for patients through this move into the PPO network with its new and advanced products.
Mesa Pharmacy has now expanded its innovative and non-addictive product line beyond topical creams to also include capsules, patches and shampoos. These prescription only products are intended to help numerous conditions such as, stretch marks, long term pain, migraines, acne, psoriasis, vitamin deficiencies, and hair loss1. "We are dedicated to providing effective alternatives to oral medications and are excited to introduce our new formulations," said Andrew Do, Pharmacist in Charge at Mesa Pharmacy. "By providing prescriptions to PPO patients, Mesa Pharmacy is able to offer products intended to aid in the recovery and wellness for more patients."
"We are passionate about providing our custom medications to a larger community and are thrilled to integrate PPOs, as this is the first step toward our goal of further diversification," said Edward F. Kurtz, Chief Operating Officer, Praxsyn Corporation. "This milestone is a significant move for the company as it allows us to expand and strengthen by creating broader opportunities for even more patients to receive our customized medication."
About Praxsyn Corporation
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients. Additional company information can be found at www.praxsyn.com.
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) including but not limited to the statement regarding the anticipated results of the commencement of processing PPO prescriptions and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.
1These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
CONTACT: Media/Investor Contact: IR@praxsyn.com 949-777-6112 ext 101